October 2012

Aveo refocuses on tivozanib, cuts 17% of workforce

Tuesday, October 30, 2012

Aveo Oncology, a cancer therapeutics company based in Cambridge, Mass., has announced a strategic restructuring designed to optimize resources and reduce expenses to ensure Aveo is well positioned for a successful launch of tivozanib in renal cell carcinoma (RCC) and continued development in other cancer types, while maintaining a focused research engine.

[Read More]

Synthetic Biologics raises $10.8M financing

Tuesday, October 30, 2012

Synthetic Biologics, an Ann Arbor, Mich.-based biotech that develops of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing.

[Read More]